Login to Your Account



Peregrine presses on with bavituximab phase III

By Catherine Shaffer
Staff Writer

Tuesday, December 31, 2013
As promised, Peregrine Pharmaceuticals Inc. has launched a Phase III trial (SUNRISE) of its lung cancer immunotherapy, bavituximab, in spite of a discouraging Phase II failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription